Inhibitory Effect of D-chiro-inositol on Both Growth and Recurrence of Breast Tumor from MDA-MB-231 Cancer Cells.
10.20307/nps.2017.23.1.35
- Author:
Yoon Seob KIM
1
;
Ji Sung PARK
;
Minji KIM
;
Bang Yeon HWANG
;
Chong Kil LEE
;
Sukgil SONG
Author Information
1. College of Pharmacy, Chungbuk National University, Chungdae-ro 1, Cheongju-si Seowon-gu, Chungcheongbuk-do, Republic of Korea. songs@chungbuk.ac.kr
- Publication Type:Original Article
- Keywords:
D-chiro-inositol;
Breast cancer;
MDA-MB-231;
Cancer stem cell;
Recurrence
- MeSH:
Animals;
Body Weight;
Breast Neoplasms*;
Breast*;
Cell Proliferation;
Doxorubicin;
Flow Cytometry;
Heterografts;
Humans;
In Vitro Techniques;
Insulin;
Mice;
Mice, Nude;
Neoplastic Stem Cells;
Phenotype;
Recurrence*;
Signal Transduction;
Stem Cells
- From:Natural Product Sciences
2017;23(1):35-39
- CountryRepublic of Korea
- Language:English
-
Abstract:
D-chiro-inositol (DCI) is a secondary messenger in insulin signal transduction. It is produced in vivo from myo-inositol via action of epimerase. In this study, we evaluated antitumor activity of DCI against human breast cancer both in vitro and in vivo. In order to determine the inhibitory effects of DCI on growth of human breast cancer cells (MDA-MB-231), two different assessment methods were implemented: MTT assay and mouse xenograft assay. MTT assay demonstrated downturn in cell proliferation by DCI treatment (1, 5, 10, 20 and 40 mM) groups by 18.3% (p<0.05), 17.2% (p<0.05), 17.5% (p<0.05), 18.4% (p<0.05), and 24.9% (p<0.01), respectively. Also, inhibition of tumor growth was investigated in mouse xenograft model. DCI was administered orally at the dose of 500 mg/kg and 1000 mg/kg body weight to treat nude mouse for 45 consecutive days. On the 45th day, tumor growth of DCI (500 mg/kg and 1000 mg/kg) groups was suppressed by 22.1% and 67.6% as mean tumor volumes were 9313.8 ± 474.1 mm³ and 3879.1 ± 1044.1 mm³, respectively. Furthermore, breast cancer stem cell (fCSC) phenotype (CD44⁺/CD24⁻) was measured using flow cytometry. On the 46th day, CSC ratios of DCI (500 mg/kg) and co-treatment with doxorubicin (4 mg/kg) and DCI (500 mg/kg) group decreased by 24.7% and 53.9% (p<0.01), respectively. Finally, from tumor recurrence assay, delay of 5 days in the co-treatment group compared to doxorubicin (4 mg/kg) alone group was observed. Based on these findings, we propose that DCI holds potential as an anti-cancer drug for treatment of breast cancer.
